Intellia Therapeutics (NTLA) Misses Q4 EPS by 15c

Intellia Therapeutics (NASDAQ: NTLA) reported Q4 EPS of ($1.09), $0.15 worse than the analyst estimate of ($0.94). Revenue for the quarter came in at $12.9 million versus the consensus estimate of $8.26 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• DA Davidson Assumes Knife River Corp. (KNF) at Buy
• Raymond James upgrades AMD, sees $201 billion server CPU market by 2030
• Tuya Inc. (TUYA) Reports In-Line Q2 EPS